<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27314331</article-id><article-id pub-id-type="pmc">4926465</article-id><article-id pub-id-type="doi">10.3390/ijms17060932</article-id><article-id pub-id-type="publisher-id">ijms-17-00932</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effect of a Prebiotic Formulation on Frailty Syndrome: A Randomized, Double-Blind Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Buigues</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00932">1</xref><xref ref-type="author-notes" rid="fn1-ijms-17-00932">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Fern&#x000e1;ndez-Garrido</surname><given-names>Julio</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00932">1</xref><xref ref-type="author-notes" rid="fn1-ijms-17-00932">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Pruimboom</surname><given-names>Leo</given-names></name><xref ref-type="aff" rid="af2-ijms-17-00932">2</xref><xref ref-type="aff" rid="af3-ijms-17-00932">3</xref></contrib><contrib contrib-type="author"><name><surname>Hoogland</surname><given-names>Aldert J.</given-names></name><xref ref-type="aff" rid="af4-ijms-17-00932">4</xref></contrib><contrib contrib-type="author"><name><surname>Navarro-Mart&#x000ed;nez</surname><given-names>Rut</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00932">1</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Mart&#x000ed;nez</surname><given-names>Mary</given-names></name><xref ref-type="aff" rid="af5-ijms-17-00932">5</xref></contrib><contrib contrib-type="author"><name><surname>Verdejo</surname><given-names>Yolanda</given-names></name><xref ref-type="aff" rid="af5-ijms-17-00932">5</xref></contrib><contrib contrib-type="author"><name><surname>Mascar&#x000f3;s</surname><given-names>Mari Carmen</given-names></name><xref ref-type="aff" rid="af5-ijms-17-00932">5</xref></contrib><contrib contrib-type="author"><name><surname>Peris</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af5-ijms-17-00932">5</xref></contrib><contrib contrib-type="author"><name><surname>Cauli</surname><given-names>Omar</given-names></name><xref ref-type="aff" rid="af1-ijms-17-00932">1</xref><xref rid="c1-ijms-17-00932" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Segura-Carretero</surname><given-names>Antonio</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>G&#x000f3;mez Caravaca</surname><given-names>Ana Maria</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-17-00932"><label>1</label>Department of Nursing, University of Valencia, Valencia 46010, Spain; <email>cristina.buigues@uv.es</email> (C.B.); <email>julio.fernandez@uv.es</email> (J.F.-G.); <email>rut.navarro@uv.es</email> (R.N.-M.)</aff><aff id="af2-ijms-17-00932"><label>2</label>Natura Foundation, Numansdorp 3281 NC, The Netherlands; <email>cpni.pruimboom@icloud.com</email></aff><aff id="af3-ijms-17-00932"><label>3</label>University of Groningen, University Medical Center Groningen (UMCG), Groningen 9712 CP, The Netherlands</aff><aff id="af4-ijms-17-00932"><label>4</label>Bonusan Besloten Vennootschap, Numansdorp 3280 AA, The Netherlands; <email>a.hoogland@bonusan.nl</email></aff><aff id="af5-ijms-17-00932"><label>5</label>GeroResidencias La Saleta, Valencia 46015, Spain; <email>mmartinez@lasaleta.com</email> (M.M.-M.); <email>supelpuig@saleta.com</email> (Y.V.); <email>supcampolivar@saleta.com</email> (M.C.M.); <email>betera@lasaleta.com</email> (C.P.)</aff><author-notes><corresp id="c1-ijms-17-00932"><label>*</label>Correspondence: <email>omar.cauli@uv.es</email>; Tel.: +34-96-386-4182</corresp><fn id="fn1-ijms-17-00932"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2016</year></pub-date><volume>17</volume><issue>6</issue><elocation-id>932</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>02</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2016</copyright-year><license><license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Aging can result in major changes in the composition and metabolic activities of bacterial populations in the gastrointestinal system and result in impaired function of the immune system. We assessed the efficacy of prebiotic Darmocare Pre<sup>&#x000ae;</sup> (Bonusan Besloten Vennootschap (BV), Numansdorp, The Netherlands) to evaluate whether the regular intake of this product can improve frailty criteria, functional status and response of the immune system in elderly people affected by the frailty syndrome. The study was a placebo-controlled, randomized, double blind design in sixty older participants aged 65 and over. The prebiotic product was composed of a mixture of inulin plus fructooligosaccharides and was compared with placebo (maltodextrin). Participants were randomized to a parallel group intervention of 13 weeks&#x02019; duration with a daily intake of Darmocare Pre<sup>&#x000ae;</sup> or placebo. Either prebiotic or placebo were administered after breakfast (between 9&#x02013;10 a.m.) dissolved in a glass of water carefully stirred just before drinking. The primary outcome was to study the effect on frailty syndrome. The secondary outcomes were effect on functional and cognitive behavior and sleep quality. Moreover, we evaluated whether prebiotic administration alters blood parameters (haemogram and biochemical analysis). The overall rate of frailty was not significantly modified by Darmocare Pre<sup>&#x000ae;</sup> administration. Nevertheless, prebiotic administration compared with placebo significantly improved two frailty criteria, e.g., exhaustion and handgrip strength (<italic>p</italic> &#x0003c; 0.01 and <italic>p</italic> &#x0003c; 0.05, respectively). No significant effects were observed in functional and cognitive behavior or sleep quality. The use of novel therapeutic approaches influencing the gut microbiota&#x02013;muscle&#x02013;brain axis could be considered for treatment of the frailty syndrome.</p></abstract><kwd-group><kwd>fatigue</kwd><kwd>biomarker</kwd><kwd>leucocytes</kwd><kwd>inflammation</kwd><kwd>aging</kwd></kwd-group></article-meta></front><body><sec id="sec1-ijms-17-00932"><title>1. Introduction</title><p>Health care for older people in western societies, with high rates of chronic diseases and mental and physical impairment, has become a challenge for every health professional. Frailty is a geriatric syndrome describing physical and functional decline that occurs as a consequence of certain diseases (e.g., cancer, chronic infection, <italic>etc.</italic>) but also even without disease. This syndrome is characterized by an increased risk for poor outcomes related with accidental falls, fractures, disability, comorbidity, health care expenditure and premature mortality [<xref rid="B1-ijms-17-00932" ref-type="bibr">1</xref>]. In a recent publication, our group has shown [<xref rid="B2-ijms-17-00932" ref-type="bibr">2</xref>] that an increase in neutrophil count and a decrease in lymphocyte count are significantly associated with less hand grip strength and low physical activity, two criteria of frailty syndrome [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>]. We wish to test with a confident perspective that any measure that alters the number of leukocytes (decrease in neutrophil count and increase in lymphocyte count) can prevent the progression of frailty syndrome since it has been consistently demonstrated that proper immune function in aging is associated with the absence of other signs and symptoms [<xref rid="B4-ijms-17-00932" ref-type="bibr">4</xref>]. The gut microbiota and their metabolites play a central role in modulating gut health and disease [<xref rid="B4-ijms-17-00932" ref-type="bibr">4</xref>,<xref rid="B5-ijms-17-00932" ref-type="bibr">5</xref>] in all age groups, especially in elderly people [<xref rid="B6-ijms-17-00932" ref-type="bibr">6</xref>]. In the elderly, there seems to be a decline in microbiota diversity [<xref rid="B7-ijms-17-00932" ref-type="bibr">7</xref>] with lower numbers of bifidobacteria, an increase in Enterobacteriaceae [<xref rid="B8-ijms-17-00932" ref-type="bibr">8</xref>] and certain Proteobacteria. Moreover, these changes are suspected to play a role in the causation of bowel disease [<xref rid="B9-ijms-17-00932" ref-type="bibr">9</xref>]. Age-related changes in gastro-intestinal physiology and function, such as greater permeability of mucosal membrane, reduced transit times, and secretion of acids by the gastric mucosa, can result in a significant change in the composition of the intestinal microbiota, marked by a decline in bifidobacterial numbers and an increase in putatively detrimental populations such as clostridia and enterobacteria [<xref rid="B10-ijms-17-00932" ref-type="bibr">10</xref>,<xref rid="B11-ijms-17-00932" ref-type="bibr">11</xref>,<xref rid="B12-ijms-17-00932" ref-type="bibr">12</xref>]. This altered composition of the gut microbiota can affect the immune system causing profound and multifaceted changes in the elderly [<xref rid="B13-ijms-17-00932" ref-type="bibr">13</xref>]. Prebiotics are food ingredients that, when selectively fermented, may alter the composition and/or activity of the intestinal microbiota and bring possible benefits to the individual&#x02019;s health. Oral administration of formulas containing prebiotics and fermented milk products may improve intestinal microbiota in this population and may contribute to the regulation of the gastro-intestinal functions and activity of the immune&#x02013;gut system [<xref rid="B14-ijms-17-00932" ref-type="bibr">14</xref>]. The potential use of prebiotics as a modulator of the immune function in older individuals has been suggested [<xref rid="B15-ijms-17-00932" ref-type="bibr">15</xref>]. The rotational of our clinical trial was based on previous <italic>in vitro</italic> studies that demonstrated the ability of prebiotics to regulate the immune response through lymphocyte regulation and subsequently the inflammatory response [<xref rid="B16-ijms-17-00932" ref-type="bibr">16</xref>,<xref rid="B17-ijms-17-00932" ref-type="bibr">17</xref>,<xref rid="B18-ijms-17-00932" ref-type="bibr">18</xref>]. Recently, studies performed in healthy humans found that administration of prebiotics increase the percentages of some lymphocyte subtypes [<xref rid="B19-ijms-17-00932" ref-type="bibr">19</xref>,<xref rid="B20-ijms-17-00932" ref-type="bibr">20</xref>].</p><p>Considering that alterations in neutrophil and lymphocyte counts are associated with frailty syndrome and, particularly with two frailty criteria, poor muscular strength and low physical activity [<xref rid="B2-ijms-17-00932" ref-type="bibr">2</xref>], the primary goal of our study was to test whether the administration of the prebiotic formulation, Darmocare Pre<sup>&#x000ae;</sup> (Bonusan Besloten Vennootschap (BV), Numansdorp, The Netherlands), improves frailty syndrome in older individuals by altering the number of neutrophil and lymphocyte counts in the blood. In addition, as secondary outcomes, we evaluated whether Darmocare Pre<sup>&#x000ae;</sup> administration improves functional capacity, and some aspects usually present in frail older people, e.g., poor quality of sleep, disabilities in daily functioning, and cognitive function.</p></sec><sec id="sec2-ijms-17-00932"><title>2. Results</title><sec id="sec2dot1-ijms-17-00932"><title>2.1. Design and Study Population</title><p>The clinical trial was conducted in 60 volunteers. The participants lived in nursing homes and were non-demented and able to walk (see inclusion and exclusion criteria in the Experimental Section). They were randomized to a parallel group intervention of 13 weeks&#x02019; duration with a daily intake of Darmocare Pre<sup>&#x000ae;</sup> or placebo (<xref ref-type="fig" rid="ijms-17-00932-f001">Figure 1</xref>). Allocation of the participants was blinded. The intervention group used Darmocare Pre<sup>&#x000ae;</sup>. The composition of Darmocare Pre<sup>&#x000ae;</sup> was Inulin min. 3375 mg fructooligosaccharides (FOS) min. 3488 mg of per level measuring spoon (of 7.5 grams): Excipients: none guaranteed to contain no genetically modified organisms, maize, soy, yeast, gluten, lactose, added saccharose, gelatine, animal substances, preservatives, artificial coloring, flavoring and aromatic substances. The placebo group used an indistinguishable placebo product, which consisted of a corresponding dose of maltodextrin. The mean energy intake in Darmocare Pre<sup>&#x000ae;</sup>-group was 1720 &#x000b1; 184 kcal/day, and in the placebo group was 1658 &#x000b1; 220 kcal/day. We did not observe any statistically significant difference (<italic>p</italic> = 0.83) between the two experimental groups regarding the energy intake. Power calculation for the study was estimated as a function of the differences in the measure between the groups that should be detected, and the standard deviation of these values, the <italic>p</italic>-value (&#x003b1; value), and sample size. The probability is 90 percent that the study will detect a treatment difference at a two-sided 0.05 significance level, if the true difference between treatments is 1.000 units. This is based on the assumption that the standard deviation of the difference in the response variables is two. The standard deviation for frailty criteria that we considered for the intervention was two (based on trial aimed to reduce frailty syndrome as a primary outcome). Thus, to achieve 90% power at a two-sided 5% significance level, and to detect a minimum difference of one piece of frailty criteria between placebo and Darmocare Pre<sup>&#x000ae;</sup>-groups, it was calculated that a sample size of a total of 44 patients will enter this two-treatment crossover study [<xref rid="B21-ijms-17-00932" ref-type="bibr">21</xref>]. Therefore, to allow for dropouts of people that could not complete the investigation, it was planned to recruit 60 volunteers.</p><p>Both prebiotic formulation and placebo were administered after breakfast (between 9&#x02013;10 a.m) dissolved in a glass of water, which was carefully stirred just before consumption. The primary outcome measured was the effect of treatment on several frailty criteria: weight loss, self-reported exhaustion, low physical activity (PA) level, slowed motor performance and weakness according to Fried <italic>et al.</italic> [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>] and as explained below. The secondary outcome was the effect on functional activity assessed by the Barthel Index, cognitive impairment by the Mini-Mental examination score and subjective quality of sleep by the Athens Scale. Moreover, we also analyzed if treatment influenced the values of common blood analytical parameters and the haemogram. Enrollment of participants and evaluations at baseline (week 0, see <xref ref-type="fig" rid="ijms-17-00932-f001">Figure 1</xref>) was performed during the first four months of 2015. Randomization was carried out once the enrollment and baseline evaluations were completed. The intervention took place between June&#x02013;September in 2015. The participants were selected based on inclusion and exclusion criteria (see study population paragraph). Baseline evaluation was performed 1&#x02013;2 months before randomization. Within one month after completion of the study, all participants were re-evaluated (frailty syndrome, functional, cognitive and sleep impairment), blood was drawn and faecal samples were collected. The present analyses included the administration of Darmocare Pre<sup>&#x000ae;</sup> or placebo during 13 week daily administration as described below.</p></sec><sec id="sec2dot2-ijms-17-00932"><title>2.2. Sample and Dropouts</title><p>A total of fifty participants completed the study (83.3%) (15 men and 35 women). The mean age of participants was 73.8 &#x000b1; 1.6 standard error of the mean (SEM) (range 66&#x02013;90 years). No significant difference (<italic>p</italic> = 0.74) was observed between the mean age of individuals in the Darmocare Pre<sup>&#x000ae;</sup> (74.2 &#x000b1; 1.6) compared to the placebo group (73.4 &#x000b1; 1.8). No significant difference was found regarding the distribution of sexes in the experimental groups (nine men and 19 women in the Darmocare Pre<sup>&#x000ae;</sup> and six men and 16 women in the placebo group). Dropout rates were significantly (<italic>p</italic> &#x0003c; 0.05) different between groups (eight participants in the Darmocare Pre<sup>&#x000ae;</sup> group stopped the treatment and two participants from the placebo group). Four participants from the Darmocare Pre<sup>&#x000ae;</sup> dropout for cramps, two participants for episodes of diarrhea and two for unknown reasons. One participant that dropped out from the placebo groups suffered from cramps, and the other one stopped for unknown reasons. Among participants that concluded the trial, nine of 22 in the Darmocare Pre<sup>&#x000ae;</sup> group referred to the appearance of gas, which lasted between 3&#x02013;8 days. In the placebo group (maltodextrin), none of the participants that concluded the trial referred to any side effects. The two experimental groups (Darmocare Pre<sup>&#x000ae;</sup> or placebo) were not significantly different at baseline (see <xref ref-type="table" rid="ijms-17-00932-t001">Table 1</xref>).</p></sec><sec id="sec2dot3-ijms-17-00932"><title>2.3. Effect of Darmocare Pre<sup>&#x000ae;</sup> Administration on Frailty Criteria</title><p>At baseline and at the end of treatment, participants fulfilled 1&#x02013;4 frailty criteria according to Fried <italic>et al.</italic> [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>]. The overall rate of frailty was not significantly modified by Darmocare Pre<sup>&#x000ae;</sup> administration. Mean frailty score was 2.8 &#x000b1; 1.0 at baseline and 2.5 &#x000b1; 0.8 after intervention in the Darmocare Pre<sup>&#x000ae;</sup> group and 2.9 &#x000b1; 0.7 at baseline and 2.8 &#x000b1; 0.8 after intervention in the placebo group. However, when we analyzed the effect on each of the frailty criteria separately, we observed a significant effect of Darmocare Pre<sup>&#x000ae;</sup> administration. There was a significant (<italic>p</italic> &#x0003c; 0.05, Mann&#x02013;Whitney test) improvement (<xref ref-type="table" rid="ijms-17-00932-t001">Table 1</xref>) in exhaustion and muscle strength in the group of patients who received Darmocare Pre<sup>&#x000ae;</sup> compared to the placebo group. Exhaustion and muscle strength were not significantly different between groups at baseline (before intervention, see <xref ref-type="table" rid="ijms-17-00932-t001">Table 1</xref>). The other criteria of frailty syndrome <italic>i.e.</italic>, weight loss, slow walking speed and reduced physical activity were not significantly different between groups neither at baseline nor after the intervention (<xref ref-type="table" rid="ijms-17-00932-t001">Table 1</xref>). The group of patients who took the prebiotics showed a reduction in fatigue score from 1.4 &#x000b1; 1.7 at baseline to 0.8 &#x000b1; 1.4 after intervention (<italic>p</italic> &#x0003c; 0.05) and, in turn, an increase in muscle strength was also observed (measured with hand strength) from 10.6 &#x000b1; 8.2 at baseline to 12.4 &#x000b1; 3.2 (<italic>p</italic> &#x0003c; 0.05) after intervention. This strength increase occurred in fact in the dominant hand in 100% of the participants in the Darmocare Pre<sup>&#x000ae;</sup> group.</p><p>We observed an improvement in some other parameters of the frailty syndrome among the group of patients taking prebiotics when comparing values at baseline and after the intervention. We measured an improvement in walking speed in the intervention group (from 8.4 &#x000b1; 6.0 s at baseline to 7.9 &#x000b1; 4.5 s. after intervention) <italic>versus</italic> an almost equal result in the placebo group before and after intervention (from 8.6 &#x000b1; 9.0 at baseline to 8.7 &#x000b1; 4.2 after). However, this improvement did not reach statistical significance. No significant differences were observed in the Athens scale for subjective sleep quality after Darmocare Pre<sup>&#x000ae;</sup> administration. The score in Athens scale was 4.18 &#x000b1; 4.73 at baseline and 4.00 &#x000b1; 4.38 after intervention in the Darmocare Pre<sup>&#x000ae;</sup> group; 3.4 &#x000b1; 3.0 at baseline and 4.5 &#x000b1; 5.3 after intervention in placebo groups (<xref ref-type="table" rid="ijms-17-00932-t001">Table 1</xref>). No significant differences were observed in the evaluation of functional activity measured with the Barthel Scale: 74.6 &#x000b1; 17.7 at baseline and 77.1 &#x000b1; 29.9 after intervention, in the Darmocare Pre<sup>&#x000ae;</sup> group, and 76.2 &#x000b1; 13.0 at baseline and 78.3 &#x000b1; 13.9 after intervention in the placebo group. No significant differences were found for the mini mental state examination (MMSE), 26.5 &#x000b1; 3.1 at baseline and 26.4 &#x000b1; 2.2 after intervention in the Darmocare Pre<sup>&#x000ae;</sup> group; and 26.1 &#x000b1; 2.2 at baseline and 25.9 &#x000b1; 2.1 after intervention in the placebo group.</p></sec><sec id="sec2dot4-ijms-17-00932"><title>2.4. Effect of Darmocare Pre<sup>&#x000ae;</sup> on Blood Analytical Parameters</title><p>We analyzed several parameters in blood: leukocytes, neutrophils, lymphocytes, monocytes, eosinophils, basophils, platelets, erythrocytes, haemoglobin, glucose, glutamic oxaloacetic transaminase (GOT), glutamic-pyruvate transaminase (GPT), high-density lipoproteins (HDL) cholesterol, low-density lipoproteins (LDL) cholesterol, triglycerides, total proteins, creatinine calcium, sodium and potassium. As shown in <xref ref-type="table" rid="ijms-17-00932-t002">Table 2</xref>, no significant differences were observed between Darmocare Pre<sup>&#x000ae;</sup> and placebo group (significance at <italic>p</italic> &#x0003c; 0.05). At baseline, no significant differences were observed in these analytical parameters between the two groups (data not shown).</p></sec></sec><sec id="sec3-ijms-17-00932"><title>3. Discussion</title><p>Improving the function of the immune&#x02013;gut axis in the elderly has been proposed as an important target for improving health through reduced disease risk and reducing the progression of frailty syndrome that represents the previous steps towards disability, dependence, morbidities and mortality in adults [<xref rid="B18-ijms-17-00932" ref-type="bibr">18</xref>]. One of the interventions to improve gut functions are the administration of prebiotics, natural available or synthetic oligosaccharides such as fructooligosaccharides (FOS) and galactooligosaccharides (GOS). Several studies found that administration of prebiotics provide beneficial effects on health [<xref rid="B18-ijms-17-00932" ref-type="bibr">18</xref>,<xref rid="B22-ijms-17-00932" ref-type="bibr">22</xref>,<xref rid="B23-ijms-17-00932" ref-type="bibr">23</xref>]. Based on this finding, we designed a randomized, placebo-controlled study in order to assess the efficacy in frailty syndromes in older individuals, as these individuals often display gastrointestinal problems and frailties that both are characterized by immune dysfunctions among other physiopathological alterations [<xref rid="B2-ijms-17-00932" ref-type="bibr">2</xref>,<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>,<xref rid="B4-ijms-17-00932" ref-type="bibr">4</xref>,<xref rid="B18-ijms-17-00932" ref-type="bibr">18</xref>,<xref rid="B24-ijms-17-00932" ref-type="bibr">24</xref>]. Our results show the following two main results: (1) prebiotic administration as Darmocare Pre<sup>&#x000ae;</sup>, consisting of a mixture of inulin and fructooligosaccharides administered orally for 13 weeks, has a significant and beneficial effect on two criteria of frailty syndrome in older people age 65 and over, namely, hand grip and exhaustion; and (2) prebiotic administration is a safe therapeutic treatment with few and tolerable side effects.</p><p>Frailty is considered a syndrome characterized by poor muscle strength that is considered highly prevalent in old age and represents a high risk factor for falls, disability, hospitalization, and mortality [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>,<xref rid="B24-ijms-17-00932" ref-type="bibr">24</xref>]. In our study, we measured frailty criteria in each participant [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>] using muscle weakness, measured by grip strength, as one of the criteria that identify frailty and sarcopenia [<xref rid="B25-ijms-17-00932" ref-type="bibr">25</xref>,<xref rid="B26-ijms-17-00932" ref-type="bibr">26</xref>,<xref rid="B27-ijms-17-00932" ref-type="bibr">27</xref>]. The molecular mechanisms leading to poor muscular strength in frail individuals have not been addressed but inflammation and inappropriate nutritional status likely play a role [<xref rid="B28-ijms-17-00932" ref-type="bibr">28</xref>]. Our study results showed a beneficial effect on muscular hand strength after Darmocare Pre<sup>&#x000ae;</sup> administration induced a beneficial effect on muscular hand strength compared to the placebo group, suggesting that prebiotics may influence the muscular system. Interestingly, a recent multicentric observational study carried out in institutionalized older adults (age &#x0003e; 70) in Spain found that oral nutritional supplement with prebiotic fiber (30% inulin, 70% fructooligosaccharides) for 12 weeks also improved handgrip strength [<xref rid="B29-ijms-17-00932" ref-type="bibr">29</xref>]. However, in this latter study, the administration of prebiotics was combined with supplementation of vitamin D and calcium, and thus no conclusion could be made about which factor was responsible for this improvement. The improvement in muscular strength afforded by the prebiotic preparation may also explain the reduced feeling of exhaustion since the two features may likely be closely related. Several mechanisms could account for the improved muscular strength and reduced fatigue found in the subjects treated with the prebiotics. For instance, the reduction in cytokine production [<xref rid="B23-ijms-17-00932" ref-type="bibr">23</xref>] might account for these effects [<xref rid="B30-ijms-17-00932" ref-type="bibr">30</xref>,<xref rid="B31-ijms-17-00932" ref-type="bibr">31</xref>]. Schiffrin <italic>et al.</italic> [<xref rid="B32-ijms-17-00932" ref-type="bibr">32</xref>] found, in a prospective, randomized, double-blind, controlled study performed in community dwelling elderly, that oral nutritional supplementation with oligosaccharides (fructooligosaccaride 1.3 g/250 mL) attenuates the expression of mRNA for pro-inflammatory cytokines tumor necrosis factor &#x003b1; (TNF-&#x003b1;) and IL-6 mRNA in blood leucocytes, whereas no significant effects were detected in the fecal gut flora or in the nutritional parameters [<xref rid="B32-ijms-17-00932" ref-type="bibr">32</xref>]. Prebiotics may have several effects upon immune function, including the growth of beneficial bacteria leading to inhibition of pathogenic growth, thereby reducing the stimulation of other proinflammatory cytokines (IL-6, IL-1) [<xref rid="B22-ijms-17-00932" ref-type="bibr">22</xref>] or reducing activation of macrophages [<xref rid="B33-ijms-17-00932" ref-type="bibr">33</xref>,<xref rid="B34-ijms-17-00932" ref-type="bibr">34</xref>]. In order to shed some light on the mechanisms by which prebiotic administration exerts its beneficial effects in frailty syndrome, we measured the concentration of C-reactive protein whose levels generally rise in response to acute inflammation, and we did not find any significant differences between groups. We also evaluated the concentration of the pro-inflammatory cytokine TNF-&#x003b1;, but we did not find any significant difference in the concentration of TNF-&#x003b1; between prebiotic and placebo groups. Other cytokines may be involved in fatigue in frail individuals, and future studies should investigate any possible biomarker of this effect. We and other groups have previously published that frailty syndrome is associated with a change in leukocyte counts, and, in particular, in neutrophil and lymphocyte counts [<xref rid="B2-ijms-17-00932" ref-type="bibr">2</xref>,<xref rid="B35-ijms-17-00932" ref-type="bibr">35</xref>,<xref rid="B36-ijms-17-00932" ref-type="bibr">36</xref>], suggesting that interventions that modify neutrophil and/or lymphocyte counts may represent new therapeutic strategies in frailty syndrome. Supporting this goal, it has been demonstrated, at least in healthy humans, that the administration of the prebiotic &#x003b2;2-1 fructan increased the percentages of lymphocyte counts in blood (CD3+CD8+ and CD8+ subtypes) compared to the placebo group [<xref rid="B19-ijms-17-00932" ref-type="bibr">19</xref>]. Administration of a formulation containing three prebiotics including galacto-oligosaccharides (also present in Darmocare Pre<sup>&#x000ae;</sup>) for 28 weeks increases the white blood cell counts in blood [<xref rid="B20-ijms-17-00932" ref-type="bibr">20</xref>]. For the reasons above, we postulated that prebiotic administration could enhance, among other mechanisms, the number of lymphocytes in the blood of frail older individuals, and, in turn, improve frailty syndrome. However, we were not able to find any significant changes in leukocyte counts in those individuals treated with Darmocare Pre<sup>&#x000ae;</sup>, suggesting that the positive effect obtained by prebiotic administration in frailty was not related to a modulation of leukopoyesis but likely to influence levels of inflammatory mediators or metabolism. Gut microbiota may directly influence muscle cells by several molecular pathways that could potentially mediate the gut microbiota&#x02013;muscle axis such as energy sparing from the diet, and in the regulation of host immunity and metabolism [<xref rid="B23-ijms-17-00932" ref-type="bibr">23</xref>,<xref rid="B37-ijms-17-00932" ref-type="bibr">37</xref>]. Thus, this needs to be evaluated in future. Scientific evidence from these reports and our results suggest that prebiotic administration can be an attractive tool to improve health in older individuals, probably through their effects on the modulation of the immune&#x02013;gut system [<xref rid="B27-ijms-17-00932" ref-type="bibr">27</xref>]. The second main result of the clinical trial refers to the safety of Darmocare Pre<sup>&#x000ae;</sup> administration in frail older individuals, which enables its use with little medical surveillance. Prebiotic administration did not significantly alter cognitive function (assessed by the MMSE), functional impairment (Barthel index), and participants did not refer to any sleep change (Athens scale) during the course of the treatment. However, it should keep in mind that even MMSE is extensively used in clinical practice, including in the primary care setting, as a screening test for dementia [<xref rid="B38-ijms-17-00932" ref-type="bibr">38</xref>,<xref rid="B39-ijms-17-00932" ref-type="bibr">39</xref>]. Thus, it could not be a sensitive tool to detect small changes in cognition after prebiotic administration. We cannot rule out that other tests more sensitive to detect cognitive alterations in non-demented people would have produced some effects considering the proposed role of immune&#x02013;gut system of brain functions. During the course of intervention with Darmocare Pre<sup>&#x000ae;</sup>, only modest side effects such as flatulence and cramping occurred in about 30% of individuals, and these symptoms disappeared during treatment, thus suggesting that administration of prebiotics could be well- tolerated and likely usable in those cases of persistence with administration of drugs for the relief of abdominal discomfort and flatulence. In around 4% of cases, the administration of Darmocare Pre<sup>&#x000ae;</sup> induced diarrhea, although a direct causality was not demonstrated. The total drop out number of the intervention group was eight out of 36 and was due to digestive tract symptoms such as cramps/diarrhea, whereas nearly 50% of the prebiotic group experienced mild flatulence. The majority of symptoms disappeared after a very short period of eight days, but eight participants still dropped out before symptoms vanished. No major adverse effects of the use of prebiotics are known next to the symptoms our participants suffered [<xref rid="B40-ijms-17-00932" ref-type="bibr">40</xref>], and these effects only seem serious with an intake of more than 30 gr/day [<xref rid="B41-ijms-17-00932" ref-type="bibr">41</xref>]. The symptoms of bloating and gaseousness are probably adaptive to chronic consumption [<xref rid="B42-ijms-17-00932" ref-type="bibr">42</xref>], which was also made evident in our study where adverse symptoms vanished after an average of eight days. Our study has several limitations. We did not analyze several immune parameters such as IL-6 and IL-10 with which we could have researched the pro- or anti-inflammatory effects of prebiotics in the elderly, and the same holds for the absence of other immunological measurements such as subpopulations of T and B lymphocytes. The small number of participants also limited the outcomes and the development of hard conclusions. Nevertheless, our results are still promising and bigger studies using clinical hard endpoints and more biochemical and immunological parameters are warranted. Another test that we could not include was total micro biome in stool; this limitation was due to financial burden. However, the improvement of several frailty parameters through the use of prebiotics is important, and when confirmed by bigger studies, could be used not only as a cure but perhaps even as a preventive measurement.</p></sec><sec id="sec4-ijms-17-00932"><title>4. Experimental Section</title><sec id="sec4dot1-ijms-17-00932"><title>4.1. Study Population</title><p>Participants were recruited from individuals living in nursing homes located in Valencia province (Spain). The inclusion criteria were the ability to get up from a chair and walk 6 m, and an age of 65 years or older. The exclusion criteria were dementia, major psychiatric disease (schizophrenia, bipolar disorders, <italic>etc.</italic>) or blindness, acute infections, or known cancers. The present study was conducted according to the guidelines laid down in the Declaration of Helsinki, and all procedures involving human participants were approved by the Ethics Committee of the University of Valencia (Valencia, Spain) (H1424156718665). Written informed consent was obtained from all participants.</p></sec><sec id="sec4dot2-ijms-17-00932"><title>4.2. Intervention</title><p>The prebiotic Darmocare Pre<sup>&#x000ae;</sup> and the placebo (maltodextrin) were physically indistinguishable. The products were always stored at room temperature. Nurses or the participants themselves dissolved one spoon of Darmocare Pre<sup>&#x000ae;</sup> or placebo in a glass of water, and it was administered in the morning shortly after breakfast (9&#x02013;10 a.m.). The intervention and placebo products were comparable in visual appearance and taste. The participants were instructed to communicate any secondary effects of gastrointestinal alteration including changes in stool consistency or defecation frequency and to maintain habitual dietary habits. The participants were interviewed about all types of potential adverse effects including the most common side effects <italic>i.e.</italic>, gas and cramping; in addition, they were asked specifically for changes in stool characteristics (consistency and frequency). All participants in the clinical trial were recruited from individuals living in nursing homes (as stated in the Experimental Section), in which diet was constantly supervised by a team of nutritionists/dietitians. In addition, in order to compare with the results on diet intervention, we estimated the energy intake in the study sample by assessment with a three-day food diary (one weekend and two weekdays) before the beginning of the study and twice during the intervention period. A nutritional program (using a macro procedure of a spreadsheet) including a food database for Spanish population was used.</p></sec><sec id="sec4dot3-ijms-17-00932"><title>4.3. Measurement of Frailty Criteria</title><p>Frailty level was measured according to the five Fried criteria [<xref rid="B3-ijms-17-00932" ref-type="bibr">3</xref>] as previously reported by our group [<xref rid="B2-ijms-17-00932" ref-type="bibr">2</xref>]. Briefly, the criteria were assessed as follows: (1) unintentional body weight loss (5 percent or 4.5 kg or more in the last year); (2) self-reported chronic fatigue: participants met the criteria if they answered &#x0201c;A few times&#x0201d;, &#x0201c;Often&#x0201d;, or &#x0201c;Most of the time&#x0201d; to the question &#x0201c;How often in the last week did you feel that everything you did was an effort?&#x0201d;, included in the Center for Epidemiologic Studies depression scale [<xref rid="B43-ijms-17-00932" ref-type="bibr">43</xref>]; (3) low physical activity level was measured using the Spanish adaptation of the Minnesota leisure time physical activity questionnaire [<xref rid="B44-ijms-17-00932" ref-type="bibr">44</xref>,<xref rid="B45-ijms-17-00932" ref-type="bibr">45</xref>,<xref rid="B46-ijms-17-00932" ref-type="bibr">46</xref>]; (4) according to the standards of the short physical performance battery [<xref rid="B47-ijms-17-00932" ref-type="bibr">47</xref>], participants who walked 4.6 m in a longer time than the worst quintile of the sex and height-adjusted sample fulfilled the reduced walking speed criterion; our values were: men taller than 173 cm: &#x02265;6 s, height &#x0003c; 173 cm: &#x02265;7 s; women taller than 159 cm: &#x02265;6 s, height &#x0003c; 159 cm: &#x02265;7 s; and (5) to measure muscle weakness, grip strength (Kg) was measured three times in each hand alternately with a hydraulic dynamometer (Jaymar, J.A. Preston, Corp., Jackson, MS, USA) according to the standards of the Hispanic established populations for epidemiologic studies of the elderly [<xref rid="B48-ijms-17-00932" ref-type="bibr">48</xref>]. Participants were considered frail if they met at least three criteria and prefrail if they met one or two. All measurements were performed by trained members of the Department of Nursing at the University of Valencia, using a questionnaire with detailed instructions.</p></sec><sec id="sec4dot4-ijms-17-00932"><title>4.4. Geriatric Assessment</title><p>Functional status was evaluated using the Barthel index that defines the ability to perform the basic activities of daily living [<xref rid="B49-ijms-17-00932" ref-type="bibr">49</xref>] and measures the level of independence related to the following 10 items: feeding, bathing, dressing, grooming, defecating, urinating, toilet use, transfers (e.g., from armchair to bed), walking, and climbing stairs. The index has a score range 0&#x02013;100, where 0 is total dependence and 100 corresponds to total independence. The MMSE test was used to detect cognitive impairment. It evaluates different items grouped into five sections: orientation, immediate memory, attention and calculation, delayed recall, and language and construction with a score range of 0&#x02013;30, the highest scores indicating better performance [<xref rid="B38-ijms-17-00932" ref-type="bibr">38</xref>]. Another important issue evaluated was sleep quality using the Athens Insomnia Scale (AIS) [<xref rid="B50-ijms-17-00932" ref-type="bibr">50</xref>]. It consists of eight items related to sleep induction, awakenings during the night, final awakening, total sleep duration, sleep quality at night, well-being, functioning capacity, and sleepiness during the day. Each item of the AIS can be rated 0&#x02013;3, (with 0 corresponding to &#x0201c;no problem at all&#x0201d; and 3 &#x0201c;very serious problem&#x0201d;). The scale has a score range 0&#x02013;24, where 0 denotes absence of any sleep-related problem and 24 means the most severe degree of insomnia.</p></sec><sec id="sec4dot5-ijms-17-00932"><title>4.5. Blood Analytical Parameters</title><p>Blood samples were obtained from each subject between 7:30 a.m and 10 a.m under at least 8 h in fasting conditions. Blood was collected by collecting 10 mL blood each into two Becton Dickinson (BD) Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ, USA) containing ethylenediaminetetraacetic acid sodium salt (EDTA). After extraction, the blood samples were allowed to stand for 15 min and were centrifuged at 1500 rpm for 10 min at room temperature. Subsequently the plasma supernatants were aliquoted and stored at &#x02212;20 &#x000b0;C until analysis. After thawing, the samples were centrifuged at 1500 rpm for 10 min at room temperature to completely remove all cells. For all other analytical determinations, residential center control blood extractions were used. Hematological parameters (white blood cells, hemoglobin, erythrocytes, and platelets) and biochemical parameters (glucose, urea, urate, cholesterol, triglycerides, creatinine, glutamic oxaloacetic transaminase (GOT), and serum glutamic pyruvic transaminase (GPT), and C-reactive protein) were measured in clinical laboratories belonging to local public health centers. Hematologic analysis included total red blood cell count (RBC) and white blood cell count (WBC) counts obtained by hemocytometer methodology (Autocrit Ultra3 Centrifuge, Becton Dickinson). Serum analytic values were determined on a laboratory chemistry analyzer (Dimension Xpand Plus Integrated Chemistry System, Siemens, Erlangen, Germany). Serum concentration of TNF-&#x003b1; was measured using a commercial enzyme-linked immunosorbent assay kit according to the manufacturer&#x02019;s instructions (TNF-&#x003b1; (ab100654), Human ELISA Kit, Abcam<sup>&#x000ae;</sup>, Cambridge, UK). To minimize assay variance, all the measurements were conducted in duplicates and on the same day.</p></sec><sec id="sec4dot6-ijms-17-00932"><title>4.6. Statistical Analysis</title><p>Descriptive statistics, including measurements of central tendency (mean), median, and range values, were used to describe all the quantitative variables. The normal distribution of each variable was estimated with the Kolmogorov&#x02013;Smirnov test. The non-parametric Mann&#x02013;Whitney U test was performed to verify any possible differences between the two experimental groups. Statistical significance was set at <italic>p</italic> &#x0003c; 0.05 and statistical analysis was performed with the software SPSS 21.0 (SPSS Inc., Chicago, IL, USA).</p></sec></sec><sec id="sec5-ijms-17-00932"><title>5. Conclusions</title><p>The use of prebiotics such as Darmocare Pre<sup>&#x000ae;</sup> in older individuals influences certain frailty symptoms and improves the levels of fatigue and muscle strength. Prebiotics could therefore be included in the total treatment protocol of people suffering especially from frailty, and as a preventive intervention in general. Nevertheless, it is necessary to identify those individuals who would benefit the most from the use of prebiotics through selected randomized trials.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by Grant number GV/043 from Conselleria de Educaci&#x000f3;-Generalitat Valenciana and a project contract between University of Valencia and Bonusan Besloten Vennootschap.</p></ack><notes><title>Author Contributions</title><p>Mary Mart&#x000ed;nez-Mart&#x000ed;nez, Yolanda Verdejo, Mari Carmen Mascar&#x000f3;s and Carlos Peris administered the prebiotic or placebo and evaluated cognitive function and functional impairment. Omar Cauli analyzed the data; Cristina Buigues, Julio Fern&#x000e1;ndez-Garrido, Rut Navarro-Mart&#x000ed;nez and Omar Cauli evaluated frailty, sleep quality, and drafted the manuscript; Omar Cauli, Leo Pruimboom and Aldert J. Hoogland revised the manuscript; Omar Cauli designed and conceived the study and was responsible for obtaining project grant funding.</p></notes><notes><title>Conflicts of Interest</title><p>Aldert J. Hoogland is a product developer in the company (Bonusan) that provided the Darmocare Pre<sup>&#x000ae;</sup> and the placebo for the study, and he performed the blinded randomization. Leo Pruimboom is a regular teacher in courses and seminars organized by Bonusan. Aldert J. Hoogland and Leo Pruimboom never saw any of the participants or saw any of the results in this study. Cristina Buigues and Julio Fern&#x000e1;ndez-Garrido wrote the manuscript. Omar Cauli and Leo Pruimboom reviewed and corrected the manuscript. The remaining authors (including Omar Cauli) declare that they have no competing interests, and they were blind to the drug treatment until the completion of the study.</p></notes><ref-list><title>References</title><ref id="B1-ijms-17-00932"><label>1.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morley</surname><given-names>J.E.</given-names></name><name><surname>Vellas</surname><given-names>B.</given-names></name><name><surname>van Kan</surname><given-names>G.A.</given-names></name><name><surname>Anker</surname><given-names>S.D.</given-names></name><name><surname>Bauer</surname><given-names>J.M.</given-names></name><name><surname>Bernabei</surname><given-names>R.</given-names></name><name><surname>Cesari</surname><given-names>M.</given-names></name><name><surname>Chumlea</surname><given-names>W.C.</given-names></name><name><surname>Doehner</surname><given-names>W.</given-names></name><name><surname>Evans</surname><given-names>J.</given-names></name><etal/></person-group>
<article-title>Frailty consensus: A call to action</article-title>
<source>J. Am. Med. Dir. Assoc.</source>
<year>2013</year>
<volume>14</volume>
<fpage>392</fpage>
<lpage>397</lpage>
<pub-id pub-id-type="doi">10.1016/j.jamda.2013.03.022</pub-id>
<pub-id pub-id-type="pmid">23764209</pub-id></element-citation></ref><ref id="B2-ijms-17-00932"><label>2.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Garrido</surname><given-names>J.</given-names></name><name><surname>Ruiz-Ros</surname><given-names>V.</given-names></name><name><surname>Buigues</surname><given-names>C.</given-names></name><name><surname>Navarro-Mart&#x000ed;nez</surname><given-names>R.</given-names></name><name><surname>Cauli</surname><given-names>O.</given-names></name></person-group>
<article-title>Clinical features of prefrail older individuals and emerging peripheral biomarkers: A systematic review</article-title>
<source>Arch. Gerontol. Geriatr.</source>
<year>2014</year>
<volume>59</volume>
<fpage>7</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.archger.2014.02.008</pub-id>
<pub-id pub-id-type="pmid">24679669</pub-id></element-citation></ref><ref id="B3-ijms-17-00932"><label>3.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fried</surname><given-names>L.P.</given-names></name><name><surname>Tangen</surname><given-names>C.M.</given-names></name><name><surname>Walston</surname><given-names>J.</given-names></name><name><surname>Newman</surname><given-names>A.B.</given-names></name><name><surname>Hirsch</surname><given-names>C.</given-names></name><name><surname>Gottdiener</surname><given-names>J.</given-names></name><name><surname>Seeman</surname><given-names>T.</given-names></name><name><surname>Tracy</surname><given-names>R.</given-names></name><name><surname>Kop</surname><given-names>W.J.</given-names></name><name><surname>Burke</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>Frailty in older adults: Evidence for a phenotype</article-title>
<source>J. Gerontol. Ser. A Biol. Sci. Med. Sci.</source>
<year>2001</year>
<volume>56</volume>
<fpage>M146</fpage>
<lpage>M156</lpage>
<pub-id pub-id-type="doi">10.1093/gerona/56.3.M146</pub-id>
<pub-id pub-id-type="pmid">11253156</pub-id></element-citation></ref><ref id="B4-ijms-17-00932"><label>4.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cho</surname><given-names>I.</given-names></name><name><surname>Blaser</surname><given-names>M.J.</given-names></name></person-group>
<article-title>The human microbiome: At the interface of health and disease</article-title>
<source>Nat. Rev. Genet.</source>
<year>2012</year>
<volume>13</volume>
<fpage>260</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.1038/nrg3182</pub-id>
<pub-id pub-id-type="pmid">22411464</pub-id></element-citation></ref><ref id="B5-ijms-17-00932"><label>5.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sekirov</surname><given-names>I.</given-names></name><name><surname>Russell</surname><given-names>S.L.</given-names></name><name><surname>Antunes</surname><given-names>L.C.M.</given-names></name><name><surname>Finlay</surname><given-names>B.B.</given-names></name></person-group>
<article-title>Gut microbiota in health and disease</article-title>
<source>Physiol. Rev.</source>
<year>2010</year>
<volume>90</volume>
<fpage>859</fpage>
<lpage>904</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00045.2009</pub-id>
<pub-id pub-id-type="pmid">20664075</pub-id></element-citation></ref><ref id="B6-ijms-17-00932"><label>6.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Claesson</surname><given-names>M.J.</given-names></name><name><surname>Cusack</surname><given-names>S.</given-names></name><name><surname>O&#x02018;Sullivan</surname><given-names>O.</given-names></name><name><surname>Greene-Diniz</surname><given-names>R.</given-names></name><name><surname>de Weerd</surname><given-names>H.</given-names></name><name><surname>Flannery</surname><given-names>E.</given-names></name><name><surname>Marchesi</surname><given-names>J.R.</given-names></name><name><surname>Falush</surname><given-names>D.</given-names></name><name><surname>Dinan</surname><given-names>T.</given-names></name><name><surname>Fitzgerald</surname><given-names>G.</given-names></name><etal/></person-group>
<article-title>Composition, variability, and temporal stability of the intestinal microbiota of the elderly</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2011</year>
<volume>108</volume>
<issue>Suppl. S1</issue>
<fpage>4586</fpage>
<lpage>4591</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1000097107</pub-id>
<pub-id pub-id-type="pmid">20571116</pub-id></element-citation></ref><ref id="B7-ijms-17-00932"><label>7.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O&#x02019;Toole</surname><given-names>P.W.</given-names></name><name><surname>Claesson</surname><given-names>M.J.</given-names></name></person-group>
<article-title>Gut microbiota: Changes throughout the lifespan from infancy to elderly</article-title>
<source>Int. Dairy J.</source>
<year>2010</year>
<volume>20</volume>
<fpage>281</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1016/j.idairyj.2009.11.010</pub-id>
</element-citation></ref><ref id="B8-ijms-17-00932"><label>8.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woodmansey</surname><given-names>E.J.</given-names></name></person-group>
<article-title>Intestinal bacteria and aging</article-title>
<source>J. Appl. Microbiol.</source>
<year>2007</year>
<volume>102</volume>
<fpage>1178</fpage>
<lpage>1186</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2672.2007.03400.x</pub-id>
<pub-id pub-id-type="pmid">17448153</pub-id></element-citation></ref><ref id="B9-ijms-17-00932"><label>9.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Roberts</surname><given-names>C.L.</given-names></name><name><surname>Keita</surname><given-names>A.V.</given-names></name><name><surname>Duncan</surname><given-names>S.H.</given-names></name><name><surname>O&#x02019;Kennedy</surname><given-names>N.</given-names></name><name><surname>S&#x000f6;derholm</surname><given-names>J.D.</given-names></name><name><surname>Rhodes</surname><given-names>J.M.</given-names></name><name><surname>Campbell</surname><given-names>B.J.</given-names></name></person-group>
<article-title>Translocation of Crohn&#x02019;s disease <italic>Escherichia coli</italic> across M-cells: Contrasting effects of soluble plant fibres and emulsifiers</article-title>
<source>Gut</source>
<year>2010</year>
<volume>59</volume>
<fpage>1331</fpage>
<lpage>1339</lpage>
<pub-id pub-id-type="doi">10.1136/gut.2009.195370</pub-id>
<pub-id pub-id-type="pmid">20813719</pub-id></element-citation></ref><ref id="B10-ijms-17-00932"><label>10.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gavini</surname><given-names>F.</given-names></name><name><surname>Cayuela</surname><given-names>C.</given-names></name><name><surname>Antoine</surname><given-names>J.-M.</given-names></name><name><surname>Lecoq</surname><given-names>C.</given-names></name><name><surname>Lefebvre</surname><given-names>B.</given-names></name><name><surname>Membr&#x000e9;</surname><given-names>J.-M.</given-names></name><name><surname>Neut</surname><given-names>C.</given-names></name></person-group>
<article-title>Differences in the distribution of bifidobacterial and enterobacterial species in human faecal microflora of three different (children, adults, elderly) age groups</article-title>
<source>Microb. Ecol. Health Dis.</source>
<year>2001</year>
<volume>13</volume>
<fpage>40</fpage>
<lpage>45</lpage>
</element-citation></ref><ref id="B11-ijms-17-00932"><label>11.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>M.J.</given-names></name><name><surname>Sharp</surname><given-names>R.</given-names></name><name><surname>Macfarlane</surname><given-names>G.T.</given-names></name></person-group>
<article-title>Variation in human intestinal microbiota with age</article-title>
<source>Dig. Liver Dis.</source>
<year>2002</year>
<volume>34</volume>
<issue>Suppl. S2</issue>
<fpage>S12</fpage>
<lpage>S18</lpage>
<pub-id pub-id-type="doi">10.1016/S1590-8658(02)80157-8</pub-id>
<pub-id pub-id-type="pmid">12408433</pub-id></element-citation></ref><ref id="B12-ijms-17-00932"><label>12.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franks</surname><given-names>A.H.</given-names></name><name><surname>Harmsen</surname><given-names>H.J.</given-names></name><name><surname>Raangs</surname><given-names>G.C.</given-names></name><name><surname>Jansen</surname><given-names>G.J.</given-names></name><name><surname>Schut</surname><given-names>F.</given-names></name><name><surname>Welling</surname><given-names>G.W.</given-names></name></person-group>
<article-title>Variations of bacterial populations in human feces measured by fluorescent <italic>in situ</italic> hybridization with group-specific 16S rRNA-targeted oligonucleotide probes</article-title>
<source>Appl. Environ. Microbiol.</source>
<year>1998</year>
<volume>64</volume>
<fpage>3336</fpage>
<lpage>3345</lpage>
<pub-id pub-id-type="pmid">9726880</pub-id></element-citation></ref><ref id="B13-ijms-17-00932"><label>13.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>C.</given-names></name><name><surname>Capri</surname><given-names>M.</given-names></name><name><surname>Monti</surname><given-names>D.</given-names></name><name><surname>Giunta</surname><given-names>S.</given-names></name><name><surname>Olivieri</surname><given-names>F.</given-names></name><name><surname>Sevini</surname><given-names>F.</given-names></name><name><surname>Panourgia</surname><given-names>M.P.</given-names></name><name><surname>Invidia</surname><given-names>L.</given-names></name><name><surname>Celani</surname><given-names>L.</given-names></name><name><surname>Scurti</surname><given-names>M.</given-names></name><etal/></person-group>
<article-title>Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans</article-title>
<source>Mech. Ageing Dev.</source>
<year>2007</year>
<volume>128</volume>
<fpage>92</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1016/j.mad.2006.11.016</pub-id>
<pub-id pub-id-type="pmid">17116321</pub-id></element-citation></ref><ref id="B14-ijms-17-00932"><label>14.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nagafuchi</surname><given-names>S.</given-names></name><name><surname>Yamaji</surname><given-names>T.</given-names></name><name><surname>Kawashima</surname><given-names>A.</given-names></name><name><surname>Saito</surname><given-names>Y.</given-names></name><name><surname>Takahashi</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Maruyama</surname><given-names>M.</given-names></name><name><surname>Akatsu</surname><given-names>H.</given-names></name></person-group>
<article-title>Effects of a formula containing two types of prebiotics, bifidogenic growth stimulator and galacto-oligosaccharide, and fermented milk products on intestinal microbiota and antibody response to influenza vaccine in elderly patients: A randomized controlled trial</article-title>
<source>Pharmaceuticals</source>
<year>2015</year>
<volume>8</volume>
<fpage>351</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="pmid">26096655</pub-id></element-citation></ref><ref id="B15-ijms-17-00932"><label>15.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vulevic</surname><given-names>J.</given-names></name><name><surname>Drakoularakou</surname><given-names>A.</given-names></name><name><surname>Yaqoob</surname><given-names>P.</given-names></name><name><surname>Tzortzis</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name></person-group>
<article-title>Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers</article-title>
<source>Am. J. Clin. Nutr.</source>
<year>2008</year>
<volume>88</volume>
<fpage>1438</fpage>
<lpage>1446</lpage>
<pub-id pub-id-type="pmid">18996881</pub-id></element-citation></ref><ref id="B16-ijms-17-00932"><label>16.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Claesson</surname><given-names>M.J.</given-names></name><name><surname>Jeffery</surname><given-names>I.B.</given-names></name><name><surname>Conde</surname><given-names>S.</given-names></name><name><surname>Power</surname><given-names>S.E.</given-names></name><name><surname>O&#x02019;Connor</surname><given-names>E.M.</given-names></name><name><surname>Cusack</surname><given-names>S.</given-names></name><name><surname>Harris</surname><given-names>H.M.B.</given-names></name><name><surname>Coakley</surname><given-names>M.</given-names></name><name><surname>Lakshminarayanan</surname><given-names>B.</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>O.</given-names></name><etal/></person-group>
<article-title>Gut microbiota composition correlates with diet and health in the elderly</article-title>
<source>Nature</source>
<year>2012</year>
<volume>488</volume>
<fpage>178</fpage>
<lpage>184</lpage>
<pub-id pub-id-type="doi">10.1038/nature11319</pub-id>
<pub-id pub-id-type="pmid">22797518</pub-id></element-citation></ref><ref id="B17-ijms-17-00932"><label>17.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groeger</surname><given-names>D.</given-names></name><name><surname>O&#x02019;Mahony</surname><given-names>L.</given-names></name><name><surname>Murphy</surname><given-names>E.F.</given-names></name><name><surname>Bourke</surname><given-names>J.F.</given-names></name><name><surname>Dinan</surname><given-names>T.G.</given-names></name><name><surname>Kiely</surname><given-names>B.</given-names></name><name><surname>Shanahan</surname><given-names>F.</given-names></name><name><surname>Quigley</surname><given-names>E.M.M.</given-names></name></person-group>
<article-title>Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut</article-title>
<source>Gut Microbes</source>
<year>2013</year>
<volume>4</volume>
<fpage>325</fpage>
<lpage>339</lpage>
<pub-id pub-id-type="doi">10.4161/gmic.25487</pub-id>
<pub-id pub-id-type="pmid">23842110</pub-id></element-citation></ref><ref id="B18-ijms-17-00932"><label>18.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cusack</surname><given-names>S.</given-names></name><name><surname>O&#x02019;Toole</surname><given-names>P.W.</given-names></name></person-group>
<article-title>Diet, the gut microbiota and healthy aging: How dietary modulation of the gut microbiota could transform the health of older populations</article-title>
<source>Agro FOOD Ind. Hi Tech</source>
<year>2013</year>
<volume>24</volume>
<fpage>54</fpage>
<lpage>57</lpage>
</element-citation></ref><ref id="B19-ijms-17-00932"><label>19.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lomax</surname><given-names>A.R.</given-names></name><name><surname>Cheung</surname><given-names>L.V.Y.</given-names></name><name><surname>Tuohy</surname><given-names>K.M.</given-names></name><name><surname>Noakes</surname><given-names>P.S.</given-names></name><name><surname>Miles</surname><given-names>E.A.</given-names></name><name><surname>Calder</surname><given-names>P.C.</given-names></name></person-group>
<article-title>&#x003b2;2-1 Fructans have a bifidogenic effect in healthy middle-aged human subjects but do not alter immune responses examined in the absence of an <italic>in vivo</italic> immune challenge: Results from a randomized controlled trial</article-title>
<source>Br. J. Nutr.</source>
<year>2012</year>
<volume>108</volume>
<fpage>1818</fpage>
<lpage>1828</lpage>
<pub-id pub-id-type="doi">10.1017/S0007114511007276</pub-id>
<pub-id pub-id-type="pmid">22244014</pub-id></element-citation></ref><ref id="B20-ijms-17-00932"><label>20.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Zhuang</surname><given-names>W.</given-names></name><name><surname>Scalabrin</surname><given-names>D.</given-names></name></person-group>
<article-title>Follow-up formula consumption in 3- to 4-year-olds and respiratory infections: An RCT</article-title>
<source>Pediatrics</source>
<year>2014</year>
<volume>133</volume>
<fpage>e1533</fpage>
<lpage>e1540</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2013-3598</pub-id>
<pub-id pub-id-type="pmid">24843061</pub-id></element-citation></ref><ref id="B21-ijms-17-00932"><label>21.</label><element-citation publication-type="book">
<article-title>Statistical Considerations for Clinical Trials and Scientific Experiments</article-title>
<publisher-name>Massachusetts General Hospital&#x02019;s Biostatistics Center</publisher-name>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="http://hedwig.mgh.harvard.edu/sample_size/size.html">http://hedwig.mgh.harvard.edu/sample_size/size.html</ext-link></comment>
<date-in-citation>(accessed on 8 September 2014)</date-in-citation>
</element-citation></ref><ref id="B22-ijms-17-00932"><label>22.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toward</surname><given-names>R.</given-names></name><name><surname>Montandon</surname><given-names>S.</given-names></name><name><surname>Walton</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name></person-group>
<article-title>Effect of prebiotics on the human gut microbiota of elderly persons</article-title>
<source>Gut Microbes</source>
<year>2012</year>
<volume>3</volume>
<fpage>57</fpage>
<lpage>60</lpage>
<pub-id pub-id-type="doi">10.4161/gmic.19411</pub-id>
<pub-id pub-id-type="pmid">22555548</pub-id></element-citation></ref><ref id="B23-ijms-17-00932"><label>23.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bindels</surname><given-names>L.B.</given-names></name><name><surname>Delzenne</surname><given-names>N.M.</given-names></name></person-group>
<article-title>Muscle wasting: The gut microbiota as a new therapeutic target?</article-title>
<source>Int. J. Biochem. Cell Biol.</source>
<year>2013</year>
<volume>45</volume>
<fpage>2186</fpage>
<lpage>2190</lpage>
<pub-id pub-id-type="doi">10.1016/j.biocel.2013.06.021</pub-id>
<pub-id pub-id-type="pmid">23831839</pub-id></element-citation></ref><ref id="B24-ijms-17-00932"><label>24.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Woods</surname><given-names>N.F.</given-names></name><name><surname>LaCroix</surname><given-names>A.Z.</given-names></name><name><surname>Gray</surname><given-names>S.L.</given-names></name><name><surname>Aragaki</surname><given-names>A.</given-names></name><name><surname>Cochrane</surname><given-names>B.B.</given-names></name><name><surname>Brunner</surname><given-names>R.L.</given-names></name><name><surname>Masaki</surname><given-names>K.</given-names></name><name><surname>Murray</surname><given-names>A.</given-names></name><name><surname>Newman</surname><given-names>A.B.</given-names></name></person-group>
<article-title>Frailty: Emergence and consequences in women aged 65 and older in the Women&#x02019;s Health Initiative Observational Study</article-title>
<source>J. Am. Geriatr. Soc.</source>
<year>2005</year>
<volume>53</volume>
<fpage>1321</fpage>
<lpage>1330</lpage>
<pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53405.x</pub-id>
<pub-id pub-id-type="pmid">16078957</pub-id></element-citation></ref><ref id="B25-ijms-17-00932"><label>25.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cooper</surname><given-names>C.</given-names></name><name><surname>Dere</surname><given-names>W.</given-names></name><name><surname>Evans</surname><given-names>W.</given-names></name><name><surname>Kanis</surname><given-names>J.A.</given-names></name><name><surname>Rizzoli</surname><given-names>R.</given-names></name><name><surname>Sayer</surname><given-names>A.A.</given-names></name><name><surname>Sieber</surname><given-names>C.C.</given-names></name><name><surname>Kaufman</surname><given-names>J.-M.</given-names></name><name><surname>Abellan van Kan</surname><given-names>G.</given-names></name><name><surname>Boonen</surname><given-names>S.</given-names></name><etal/></person-group>
<article-title>Frailty and sarcopenia: Definitions and outcome parameters</article-title>
<source>Osteoporos. Int.</source>
<year>2012</year>
<volume>23</volume>
<fpage>1839</fpage>
<lpage>1848</lpage>
<pub-id pub-id-type="doi">10.1007/s00198-012-1913-1</pub-id>
<pub-id pub-id-type="pmid">22290243</pub-id></element-citation></ref><ref id="B26-ijms-17-00932"><label>26.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Evans</surname><given-names>W.J.</given-names></name><name><surname>Paolisso</surname><given-names>G.</given-names></name><name><surname>Abbatecola</surname><given-names>A.M.</given-names></name><name><surname>Corsonello</surname><given-names>A.</given-names></name><name><surname>Bustacchini</surname><given-names>S.</given-names></name><name><surname>Strollo</surname><given-names>F.</given-names></name><name><surname>Lattanzio</surname><given-names>F.</given-names></name></person-group>
<article-title>Frailty and muscle metabolism dysregulation in the elderly</article-title>
<source>Biogerontology</source>
<year>2010</year>
<volume>11</volume>
<fpage>527</fpage>
<lpage>536</lpage>
<pub-id pub-id-type="doi">10.1007/s10522-010-9297-0</pub-id>
<pub-id pub-id-type="pmid">20683658</pub-id></element-citation></ref><ref id="B27-ijms-17-00932"><label>27.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marzetti</surname><given-names>E.E.</given-names></name><name><surname>Calvani</surname><given-names>R.R.</given-names></name><name><surname>Bernabei</surname><given-names>R.R.</given-names></name><name><surname>Leeuwenburgh</surname><given-names>C.C.</given-names></name></person-group>
<article-title>Apoptosis in skeletal myocytes: A potential target for interventions against sarcopenia and physical frailty&#x02014;A mini-review</article-title>
<source>Gerontology</source>
<year>2012</year>
<volume>58</volume>
<fpage>99</fpage>
<lpage>106</lpage>
<pub-id pub-id-type="doi">10.1159/000330064</pub-id>
<pub-id pub-id-type="pmid">21952604</pub-id></element-citation></ref><ref id="B28-ijms-17-00932"><label>28.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buch</surname><given-names>A.</given-names></name><name><surname>Carmeli</surname><given-names>E.</given-names></name><name><surname>Boker</surname><given-names>L.K.</given-names></name><name><surname>Marcus</surname><given-names>Y.</given-names></name><name><surname>Shefer</surname><given-names>G.</given-names></name><name><surname>Kis</surname><given-names>O.</given-names></name><name><surname>Berner</surname><given-names>Y.</given-names></name><name><surname>Stern</surname><given-names>N.</given-names></name></person-group>
<article-title>Muscle function and fat content in relation to sarcopenia, obesity and frailty of old age&#x02014;An overview</article-title>
<source>Exp. Gerontol.</source>
<year>2016</year>
<volume>76</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2016.01.008</pub-id>
<pub-id pub-id-type="pmid">26785313</pub-id></element-citation></ref><ref id="B29-ijms-17-00932"><label>29.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abizanda</surname><given-names>P.</given-names></name><name><surname>Lopez</surname><given-names>M.D.</given-names></name><name><surname>Garcia</surname><given-names>V.P.</given-names></name><name><surname>de Dios Estrella</surname><given-names>J.</given-names></name><name><surname>da Silva Gonzalez</surname><given-names>A.</given-names></name><name><surname>Vilardell</surname><given-names>N.B.</given-names></name><name><surname>Torres</surname><given-names>K.A.</given-names></name></person-group>
<article-title>Effects of an oral nutritional supplementation plus physical exercise intervention on the physical function, nutritional status, and quality of life in frail institutionalized older adults: The ACTIVNES study</article-title>
<source>J. Am. Med. Dir. Assoc.</source>
<year>2015</year>
<volume>16</volume>
<fpage>439.e9</fpage>
<lpage>439.e16</lpage>
<pub-id pub-id-type="doi">10.1016/j.jamda.2015.02.005</pub-id>
<pub-id pub-id-type="pmid">25841327</pub-id></element-citation></ref><ref id="B30-ijms-17-00932"><label>30.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dell&#x02019;Osso</surname><given-names>L.</given-names></name><name><surname>Bazzichi</surname><given-names>L.</given-names></name><name><surname>Baroni</surname><given-names>S.</given-names></name><name><surname>Falaschi</surname><given-names>V.</given-names></name><name><surname>Conversano</surname><given-names>C.</given-names></name><name><surname>Carmassi</surname><given-names>C.</given-names></name><name><surname>Marazziti</surname><given-names>D.</given-names></name></person-group>
<article-title>The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome</article-title>
<source>Clin. Exp. Rheumatol.</source>
<year>2015</year>
<volume>33</volume>
<fpage>S109</fpage>
<lpage>S116</lpage>
<pub-id pub-id-type="pmid">25786052</pub-id></element-citation></ref><ref id="B31-ijms-17-00932"><label>31.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lasselin</surname><given-names>J.</given-names></name><name><surname>Capuron</surname><given-names>L.</given-names></name></person-group>
<article-title>Chronic low-grade inflammation in metabolic disorders: Relevance for behavioral symptoms</article-title>
<source>Neuroimmunomodulation</source>
<year>2014</year>
<volume>21</volume>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">24557041</pub-id></element-citation></ref><ref id="B32-ijms-17-00932"><label>32.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schiffrin</surname><given-names>E.J.</given-names></name><name><surname>Thomas</surname><given-names>D.R.</given-names></name><name><surname>Kumar</surname><given-names>V.B.</given-names></name><name><surname>Brown</surname><given-names>C.</given-names></name><name><surname>Hager</surname><given-names>C.</given-names></name><name><surname>Van&#x02019;t Hof</surname><given-names>M.A.</given-names></name><name><surname>Morley</surname><given-names>J.E.</given-names></name><name><surname>Guigoz</surname><given-names>Y.</given-names></name></person-group>
<article-title>Systemic inflammatory markers in older persons: The effect of oral nutritional supplementation with prebiotics</article-title>
<source>J. Nutr. Health Aging</source>
<year>2007</year>
<volume>11</volume>
<fpage>475</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="pmid">17985062</pub-id></element-citation></ref><ref id="B33-ijms-17-00932"><label>33.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeong</surname><given-names>J.-J.</given-names></name><name><surname>Kim</surname><given-names>K.-A.</given-names></name><name><surname>Jang</surname><given-names>S.-E.</given-names></name><name><surname>Woo</surname><given-names>J.-Y.</given-names></name><name><surname>Han</surname><given-names>M.J.</given-names></name><name><surname>Kim</surname><given-names>D.-H.</given-names></name></person-group>
<article-title>Orally administrated <italic>Lactobacillus pentosus</italic> var. <italic>plantarum</italic> C29 ameliorates age-dependent colitis by inhibiting the nuclear factor-kappa B signaling pathway via the regulation of lipopolysaccharide production by gut microbiota</article-title>
<source>PLoS ONE</source>
<year>2015</year>
<volume>10</volume>
<elocation-id>932</elocation-id>
</element-citation></ref><ref id="B34-ijms-17-00932"><label>34.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Staudacher</surname><given-names>H.M.</given-names></name><name><surname>Whelan</surname><given-names>K.</given-names></name></person-group>
<article-title>Altered gastrointestinal microbiota in irritable bowel syndrome and its modification by diet: Probiotics, prebiotics and the low FODMAP diet</article-title>
<source>Proc. Nutr. Soc.</source>
<year>2016</year>
<volume>24</volume>
<fpage>1</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="doi">10.1017/S0029665116000021</pub-id>
<pub-id pub-id-type="pmid">26908093</pub-id></element-citation></ref><ref id="B35-ijms-17-00932"><label>35.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>R.E.</given-names></name><name><surname>O&#x02019;Mahony</surname><given-names>M.S.</given-names></name><name><surname>Savva</surname><given-names>G.M.</given-names></name><name><surname>Calver</surname><given-names>B.L.</given-names></name><name><surname>Woodhouse</surname><given-names>K.W.</given-names></name></person-group>
<article-title>Inflammation and frailty measures in older people</article-title>
<source>J. Cell. Mol. Med.</source>
<year>2009</year>
<volume>13</volume>
<fpage>3103</fpage>
<lpage>3109</lpage>
<pub-id pub-id-type="doi">10.1111/j.1582-4934.2009.00733.x</pub-id>
<pub-id pub-id-type="pmid">19438806</pub-id></element-citation></ref><ref id="B36-ijms-17-00932"><label>36.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Leng</surname><given-names>S.X.</given-names></name><name><surname>Xue</surname><given-names>Q.L.</given-names></name><name><surname>Tian</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Yeh</surname><given-names>S.-H.</given-names></name><name><surname>Fried</surname><given-names>L.P.</given-names></name></person-group>
<article-title>Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: Results from the Women&#x02019;s Health and Aging Studies I</article-title>
<source>Exp. Gerontol.</source>
<year>2009</year>
<volume>44</volume>
<fpage>511</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1016/j.exger.2009.05.005</pub-id>
<pub-id pub-id-type="pmid">19457449</pub-id></element-citation></ref><ref id="B37-ijms-17-00932"><label>37.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Backhed</surname><given-names>F.</given-names></name><name><surname>Manchester</surname><given-names>J.K.</given-names></name><name><surname>Semenkovich</surname><given-names>C.F.</given-names></name><name><surname>Gordon</surname><given-names>J.I.</given-names></name></person-group>
<article-title>Mechanisms underlying the resistance to diet-induced obesity in germ-free mice</article-title>
<source>Proc. Natl. Acad. Sci. USA</source>
<year>2007</year>
<volume>104</volume>
<fpage>979</fpage>
<lpage>984</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0605374104</pub-id>
<pub-id pub-id-type="pmid">17210919</pub-id></element-citation></ref><ref id="B38-ijms-17-00932"><label>38.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Folstein</surname><given-names>M.F.</given-names></name><name><surname>Folstein</surname><given-names>S.E.</given-names></name><name><surname>McHugh</surname><given-names>P.R.</given-names></name></person-group>
<article-title>&#x0201c;Mini-Mental state.&#x0201d; A practical method for grading the cognitive state of patients for the clinician</article-title>
<source>J. Psychiatr. Res.</source>
<year>1975</year>
<volume>12</volume>
<fpage>189</fpage>
<lpage>198</lpage>
<pub-id pub-id-type="doi">10.1016/0022-3956(75)90026-6</pub-id>
<pub-id pub-id-type="pmid">1202204</pub-id></element-citation></ref><ref id="B39-ijms-17-00932"><label>39.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galvin</surname><given-names>J.E.</given-names></name><name><surname>Sadowsky</surname><given-names>C.H.</given-names></name></person-group>
<article-title>Practical guidelines for the recognition and diagnosis of dementia</article-title>
<source>J. Am. Board Fam. Med.</source>
<year>2012</year>
<volume>25</volume>
<fpage>367</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.3122/jabfm.2012.03.100181</pub-id>
<pub-id pub-id-type="pmid">22570400</pub-id></element-citation></ref><ref id="B40-ijms-17-00932"><label>40.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendaus</surname><given-names>M.A.</given-names></name><name><surname>Jomha</surname><given-names>F.A.</given-names></name><name><surname>Ehlayel</surname><given-names>M.</given-names></name></person-group>
<article-title>Allergic diseases among children: Nutritional prevention and intervention</article-title>
<source>Ther. Clin. Risk Manag.</source>
<year>2016</year>
<volume>12</volume>
<fpage>361</fpage>
<lpage>372</lpage>
<pub-id pub-id-type="doi">10.2147/TCRM.S98100</pub-id>
<pub-id pub-id-type="pmid">27022267</pub-id></element-citation></ref><ref id="B41-ijms-17-00932"><label>41.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pereira</surname><given-names>D.I.A.</given-names></name><name><surname>Gibson</surname><given-names>G.R.</given-names></name></person-group>
<article-title>Effects of consumption of probiotics and prebiotics on serum lipid levels in humans</article-title>
<source>Crit. Rev. Biochem. Mol. Biol.</source>
<year>2002</year>
<volume>37</volume>
<fpage>259</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1080/10409230290771519</pub-id>
<pub-id pub-id-type="pmid">12236466</pub-id></element-citation></ref><ref id="B42-ijms-17-00932"><label>42.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marteau</surname><given-names>P.</given-names></name><name><surname>Seksik</surname><given-names>P.</given-names></name></person-group>
<article-title>Tolerance of probiotics and prebiotics</article-title>
<source>J. Clin. Gastroenterol.</source>
<year>2004</year>
<volume>38</volume>
<fpage>S67</fpage>
<lpage>S69</lpage>
<pub-id pub-id-type="doi">10.1097/01.mcg.0000128929.37156.a7</pub-id>
<pub-id pub-id-type="pmid">15220662</pub-id></element-citation></ref><ref id="B43-ijms-17-00932"><label>43.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Radloff</surname><given-names>L.S.</given-names></name></person-group>
<article-title>The CES-D scale: A self-report depression scale for research in the general population</article-title>
<source>Appl. Psychol. Meas.</source>
<year>1977</year>
<volume>1</volume>
<fpage>385</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1177/014662167700100306</pub-id>
</element-citation></ref><ref id="B44-ijms-17-00932"><label>44.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elosua</surname><given-names>R.</given-names></name><name><surname>Marrugat</surname><given-names>J.</given-names></name><name><surname>Molina</surname><given-names>L.</given-names></name><name><surname>Pons</surname><given-names>S.</given-names></name><name><surname>Pujol</surname><given-names>E.</given-names></name></person-group>
<article-title>Validation of the Minnesota leisure time physical activity questionnaire in Spanish men</article-title>
<source>Am. J. Epidemiol.</source>
<year>1994</year>
<volume>139</volume>
<fpage>1197</fpage>
<lpage>1209</lpage>
<pub-id pub-id-type="pmid">8209878</pub-id></element-citation></ref><ref id="B45-ijms-17-00932"><label>45.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Elosua</surname><given-names>R.R.</given-names></name><name><surname>Garcia</surname><given-names>M.M.</given-names></name><name><surname>Aguilar</surname><given-names>A.A.</given-names></name><name><surname>Molina</surname><given-names>L.L.</given-names></name><name><surname>Covas</surname><given-names>M.I.M.</given-names></name><name><surname>Marrugat</surname><given-names>J.J.</given-names></name></person-group>
<article-title>Validation of the Minnesota leisure time physical activity questionnaire in Spanish women. Investigators of the MARATDON group</article-title>
<source>Med. Sci. Sports Exerc.</source>
<year>2000</year>
<volume>32</volume>
<fpage>1431</fpage>
<lpage>1437</lpage>
<pub-id pub-id-type="doi">10.1097/00005768-200008000-00011</pub-id>
<pub-id pub-id-type="pmid">10949009</pub-id></element-citation></ref><ref id="B46-ijms-17-00932"><label>46.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ruiz Comellas</surname><given-names>A.</given-names></name><name><surname>Pera</surname><given-names>G.</given-names></name><name><surname>Baena-D&#x000ed;ez</surname><given-names>J.M.</given-names></name><name><surname>Mundet Tudur&#x000ed;</surname><given-names>X.</given-names></name><name><surname>Alzamora Sas</surname><given-names>T.</given-names></name><name><surname>Elosua</surname><given-names>R.</given-names></name><name><surname>Tor&#x000e1;n Monserrat</surname><given-names>P.</given-names></name><name><surname>Heras</surname><given-names>A.</given-names></name><name><surname>For&#x000e9;s Raurell</surname><given-names>R.</given-names></name><name><surname>Fust&#x000e9; Gamisans</surname><given-names>M.</given-names></name></person-group>
<article-title>Validaci&#x000f3;n de una versi&#x000f3;n reducida en espa&#x000f1;ol del cuestionario de actividad f&#x000ed;sica en el tiempo libre de Minnesota (VREM)</article-title>
<source>Rev. Esp. Salud P&#x000fa;blica</source>
<year>2012</year>
<volume>86</volume>
<fpage>495</fpage>
<lpage>508</lpage>
<comment>(In Spanish)</comment>
<pub-id pub-id-type="pmid">23223762</pub-id></element-citation></ref><ref id="B47-ijms-17-00932"><label>47.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guralnik</surname><given-names>J.M.J.</given-names></name><name><surname>Simonsick</surname><given-names>E.M.E.</given-names></name><name><surname>Ferrucci</surname><given-names>L.L.</given-names></name><name><surname>Glynn</surname><given-names>R.J.R.</given-names></name><name><surname>Berkman</surname><given-names>L.F.L.</given-names></name><name><surname>Blazer</surname><given-names>D.G.D.</given-names></name><name><surname>Scherr</surname><given-names>P.A.P.</given-names></name><name><surname>Wallace</surname><given-names>R.B.R.</given-names></name></person-group>
<article-title>A short physical performance battery assessing lower extremity function: Association with self-reported disability and prediction of mortality and nursing home admission</article-title>
<source>J. Gerontol.</source>
<year>1994</year>
<volume>49</volume>
<fpage>M85</fpage>
<lpage>M94</lpage>
<pub-id pub-id-type="doi">10.1093/geronj/49.2.M85</pub-id>
<pub-id pub-id-type="pmid">8126356</pub-id></element-citation></ref><ref id="B48-ijms-17-00932"><label>48.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ottenbacher</surname><given-names>K.J.</given-names></name><name><surname>Branch</surname><given-names>L.G.</given-names></name><name><surname>Ray</surname><given-names>L.</given-names></name><name><surname>Gonzales</surname><given-names>V.A.</given-names></name><name><surname>Peek</surname><given-names>M.K.</given-names></name><name><surname>Hinman</surname><given-names>M.R.</given-names></name></person-group>
<article-title>The reliability of upper- and lower-extremity strength testing in a community survey of older adults</article-title>
<source>Arch. Phys. Med. Rehabil.</source>
<year>2002</year>
<volume>83</volume>
<fpage>1423</fpage>
<lpage>1427</lpage>
<pub-id pub-id-type="doi">10.1053/apmr.2002.34619</pub-id>
<pub-id pub-id-type="pmid">12370879</pub-id></element-citation></ref><ref id="B49-ijms-17-00932"><label>49.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mahoney</surname><given-names>F.I.</given-names></name><name><surname>Barthel</surname><given-names>D.W.</given-names></name></person-group>
<article-title>Functional evaluation: The Barthel index</article-title>
<source>Md. State Med. J.</source>
<year>1965</year>
<volume>14</volume>
<fpage>61</fpage>
<lpage>65</lpage>
<pub-id pub-id-type="pmid">14258950</pub-id></element-citation></ref><ref id="B50-ijms-17-00932"><label>50.</label><element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Soldatos</surname><given-names>C.R.</given-names></name><name><surname>Dikeos</surname><given-names>D.G.</given-names></name><name><surname>Paparrigopoulos</surname><given-names>T.J.</given-names></name></person-group>
<article-title>Athens Insomnia Scale: Validation of an instrument based on ICD-10 criteria</article-title>
<source>J. Psychosom. Res.</source>
<year>2000</year>
<volume>48</volume>
<fpage>555</fpage>
<lpage>560</lpage>
<pub-id pub-id-type="doi">10.1016/S0022-3999(00)00095-7</pub-id>
<pub-id pub-id-type="pmid">11033374</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="ijms-17-00932-f001" position="float"><label>Figure 1</label><caption><p>Design of the clinical study. N: number of individuals.</p></caption><graphic xlink:href="ijms-17-00932-g001"/></fig><table-wrap id="ijms-17-00932-t001" position="float"><object-id pub-id-type="pii">ijms-17-00932-t001_Table 1</object-id><label>Table 1</label><caption><p>Frailty criteria and geriatric evaluation at baseline and post-treatment with Darmocare Pre<sup>&#x000ae;</sup> or placebo. * <italic>p</italic> &#x0003c; 0.05; ** <italic>p</italic> &#x0003c; 0.01.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Variable</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Baseline</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Significance</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Post-Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Significance</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo Group <break/>(<italic>n</italic> = 22)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dermocare Pre<sup>&#x000ae;</sup><break/>(<italic>n</italic> = 28)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Placebo Group<break/>(<italic>n</italic> = 22)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dermocare Pre<sup>&#x000ae;</sup><break/>(<italic>n</italic> = 28)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exhaustion (score 0&#x02013;3: 0 &#x0201c;never&#x0201d;; 1 &#x0201c;A few times&#x0201d; (1&#x02013;2 days per week); 2 &#x0201c;Often&#x0201d; (3&#x02013;4 days per week); or 3 &#x0201c;Most of the time&#x0201d; (almost each day))</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.1 &#x000b1; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 &#x000b1; 1.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.74</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.7 &#x000b1; 1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8 &#x000b1; 1.4 **</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Slow walk (s) (time needed to walk 4.6 m)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6 &#x000b1; 9.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.4 &#x000b1; 6.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.7 &#x000b1; 4.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.9 &#x000b1; 4.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.48</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Grip strength (right hand, kg)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.5 &#x000b1; 5.7</td><td align="center" valign="middle" rowspan="1" colspan="1">10.6 &#x000b1; 8.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61</td><td align="center" valign="middle" rowspan="1" colspan="1">10.2 &#x000b1; 4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.4 &#x000b1; 3.2 *</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Grip strength (left hand, kg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.2 &#x000b1; 5.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1 &#x000b1; 7.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.1 &#x000b1; 3.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.8 &#x000b1; 3.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Self health-perception (score 0&#x02013;10, being 0 the worst and 10 the best)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1 &#x000b1; 2.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.1 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.8 &#x000b1; 2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.8 &#x000b1; 2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.96</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Body mass index</td><td align="center" valign="middle" rowspan="1" colspan="1">26.1 &#x000b1; 4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">25.8 &#x000b1; 4.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td><td align="center" valign="middle" rowspan="1" colspan="1">26.0 &#x000b1; 3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">25.9 &#x000b1; 4.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Athens insomnia scale</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4 &#x000b1; 3.0</td><td align="center" valign="middle" rowspan="1" colspan="1">4.1 &#x000b1; 4.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5 &#x000b1; 5.3</td><td align="center" valign="middle" rowspan="1" colspan="1">4.0 &#x000b1; 4.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Barthel index</td><td align="center" valign="middle" rowspan="1" colspan="1">76.2 &#x000b1; 13.0</td><td align="center" valign="middle" rowspan="1" colspan="1">74.6 &#x000b1; 17.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td><td align="center" valign="middle" rowspan="1" colspan="1">78.3 &#x000b1; 13.9</td><td align="center" valign="middle" rowspan="1" colspan="1">77.1 &#x000b1; 29.9</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mini&#x02013;Mental state examination</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.1 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.5 &#x000b1; 3.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25.9 &#x000b1; 2.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">26.4 &#x000b1; 2.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.85</td></tr></tbody></table></table-wrap><table-wrap id="ijms-17-00932-t002" position="float"><object-id pub-id-type="pii">ijms-17-00932-t002_Table 2</object-id><label>Table 2</label><caption><p>Blood analysis and haemogram after treatment with Darmocare Pre<sup>&#x000ae;</sup> or the placebo. GOT: glutamic oxaloacetic transaminase; GPT: glutamic-pyruvate transaminase; HDL: high-density lipoproteins; LDL: low-density lipoproteins; TNF: tumor necrosis factor &#x003b1;.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variable</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Placebo Group (<italic>n</italic> = 22)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Darmocare Pre<sup>&#x000ae;</sup> (<italic>n</italic> = 28)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic>p</italic> Value</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Leukocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.6 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">7.7 &#x000b1; 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Neutrophils (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">4.6 &#x000b1; 0.3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lymphocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.2 &#x000b1; 0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">2.3 &#x000b1; 0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.64</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Monocytes (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.61 &#x000b1; 0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 &#x000b1; 0.03</td><td align="center" valign="middle" rowspan="1" colspan="1">0.23</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Eosinophils (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22 &#x000b1; 0.04</td><td align="center" valign="middle" rowspan="1" colspan="1">0.22 &#x000b1; 0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Basophils (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.03 &#x000b1; 0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">1.00</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Platelets (&#x000d7;10<sup>3</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">220 &#x000b1; 28</td><td align="center" valign="middle" rowspan="1" colspan="1">225 &#x000b1; 36</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Erythrocytes (&#x000d7;10<sup>6</sup>/&#x000b5;L)</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0 &#x000b1; 0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8 &#x000b1; 0.7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Haemoglobin (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.8 &#x000b1; 1.3</td><td align="center" valign="middle" rowspan="1" colspan="1">12.9 &#x000b1; 1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">95 &#x000b1; 11</td><td align="center" valign="middle" rowspan="1" colspan="1">92 &#x000b1; 10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Urea (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">44 &#x000b1; 5</td><td align="center" valign="middle" rowspan="1" colspan="1">40 &#x000b1; 3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.48</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GOT (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 &#x000b1; 3</td><td align="center" valign="middle" rowspan="1" colspan="1">27 &#x000b1; 4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.85</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GPT (U/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">25 &#x000b1; 2</td><td align="center" valign="middle" rowspan="1" colspan="1">24 &#x000b1; 4</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HDL cholesterol (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">46 &#x000b1; 6</td><td align="center" valign="middle" rowspan="1" colspan="1">44 &#x000b1; 7</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">LDL cholesterol (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">120 &#x000b1; 9</td><td align="center" valign="middle" rowspan="1" colspan="1">126 &#x000b1; 11</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Triglycerides (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">131 &#x000b1; 21</td><td align="center" valign="middle" rowspan="1" colspan="1">122 &#x000b1; 16</td><td align="center" valign="middle" rowspan="1" colspan="1">0.73</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total proteins (g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.5 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">7.4 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71 &#x000b1; 0.10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74 &#x000b1; 0.15</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Calcium (mg/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6 &#x000b1; 1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">8.9 &#x000b1; 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sodium (mEq/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">140 &#x000b1; 3</td><td align="center" valign="middle" rowspan="1" colspan="1">141 &#x000b1; 3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Potassium (mEq/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.7 &#x000b1; 0.8</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8 &#x000b1; 0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">C-reactive protein (mg/L)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.8 &#x000b1; 1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">4.9 &#x000b1; 1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TNF-&#x003b1; (pg/mL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.8 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.0 &#x000b1; 0.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.60</td></tr></tbody></table></table-wrap></floats-group></article>